Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (3) , 668-671
- https://doi.org/10.1016/j.bmcl.2005.10.037
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptaseBioorganic & Medicinal Chemistry Letters, 2005
- Expedient Parallel Synthesis of 2-Amino-4-heteroarylpyrimidinesOrganic Letters, 2005
- Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 VariantsJournal of Medicinal Chemistry, 2004
- Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125Journal of the American Chemical Society, 2003
- Selective deprotection of either alkyl or aryl silyl ethers from aryl, alkyl bis-silyl ethersTetrahedron Letters, 2002
- Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral AgentAntimicrobial Agents and Chemotherapy, 2002
- Prediction of drug solubility from structurePublished by Elsevier ,2002
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TlBO) Derivatives. 4Journal of Medicinal Chemistry, 1995
- Estimation and Correlation of Drug Water Solubility with Pharmacological Parameters Required for Biological ActivityJournal of Pharmaceutical Sciences, 1994